Monograph Details
|
|
Infections & Infestations
> Viral infections
|
|
SELZENTRY |
| Manufacturer |
|
Pfizer Labs |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
CCR5 co-receptor antagonist. |
| Generic Name |
|
Maraviroc 150mg, 300mg; tabs. |
| Indications |
|
HIV-1 infection in treatment-experienced adults infected with only CCR5-tropic HIV-1 detectable, who have evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals. |
| Children |
<16yrs: not recommended.
|
| Adults |
|
Swallow whole. ≥16yrs: Concomitant CYP3A inhibitors (eg, PIs except tipranavir/ritonavir, delavirdine, ketoconazole, itraconazole, clarithromycin, nefazodone, telithromycin) (with or without a CYP3A inducer): 150mg twice daily. Other concomitant drugs, including tipranavir/ritonavir, nevirapine, NRTIs, enfuvirtide: 300mg twice daily. Concomitant CYP3A inducers (eg, efavirenz, rifampin, carbamazepine, phenobarbital, phenytoin) (without a strong CYP3A inhibitor): 600mg twice daily. Renal dysfunction (CrCl<50mL/min) and CYP3A inhibitors: monitor closely for side effects (eg, dizziness). |
| Precautions |
|
Liver dysfunction or disease. Reevaluate if hepatitis or elevated LFTs develop. Cardiovascular risk factors. Postural hypotension. Monitor for immune reconstitution syndrome, infections, malignancies. Pregnancy (Cat. B). Nursing mothers: not recommended. |
| Interactions |
|
Concomitant St. John's wort: not recommended. May affect, or be affected by, CYP3A inhibitors or inducers and drugs affected by p-glycoprotein (eg, potentiated by ketoconazole, lopinavir/ritonavir, ritonavir, saquinavir, atazanavir; antagonized by rifampin, efavirenz). Caution with antihypertensives. |
| Adverse Reactions |
|
Cough, pyrexia, upper respiratory infections, rash, musculoskeletal symptoms, abdominal pain, dizziness; hepatotoxicity (may be preceded by systemic allergic reaction; immediately evaluate if occurs); others (see literature). |
| How Supplied |
|
Tabs—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
